Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Viking TherapeuticsSTU:1VT -1.70%38 Equity-to-Asset is 0.78 as of Jun. 2026, which is 19% below its 10-year median of 0.96. GuruFocus rates STU:1VT with a GF Score™ of 38/100. The stock has 3 warning signs investors should review. Among 1,416 Biotechnology companies, Viking Therapeutics ranks better than 62.29% on this metric.
Equity to Asset ratio can vary greatly across different industries, as they have different capital structure. A company with smaller Equity to Asset ratio (more leveraged) may have higher ROE % because of the leverage.
For banks, the required minimum Equity to Asset ratio by regulation is 5%. Some stronger banks may have Equity to Asset Ratio of more than 10%.
Viking Therapeutics Equity-to-Asset Related Terms
Viking Therapeutics Equity-to-Asset Historical Data
* Premium members only.
The historical data trend for Viking Therapeutics's Equity-to-Asset can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
STU:1VT vs DYN, CELC, RLAY: Equity-to-Asset Comparison
For the Biotechnology subindustry, Viking Therapeutics's Equity-to-Asset, along with its competitors' market caps and Equity-to-Asset data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Viking Therapeutics Equity-to-Asset vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Viking Therapeutics's Equity-to-Asset distribution charts can be found below:
* The bar in red indicates where Viking Therapeutics's Equity-to-Asset falls into.
Equity to Asset ratio measures the ratios of the portion of the asset owned by shareholders out of the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.
Equity to Asset ratio is calculated by dividing total stockholders equity by total asset.
Viking Therapeutics's Equity to Asset Ratio for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Viking Therapeutics (STU:1VT) has a Equity-to-Asset of 0.78 as of Jun. 2026. Equity-to-asset ratio equals total company equity divided by total assets. It measures financial leverage. View historical data on Viking Therapeutics and its competitors. This is 19% below median its historical median of 0.96. Over the past decade, Viking Therapeutics' Equity-to-Asset has ranged from 0.19 to 0.99. According to the industry distribution chart, Viking Therapeutics ranks #534 out of 1416 companies in the Biotechnology industry, placing it in the top 37.7%.
Is Viking Therapeutics' Equity-to-Asset too high?
Viking Therapeutics' current Equity-to-Asset of 0.78 is 19% below median its 10-year median of 0.96. Over the past 10 years, this metric has ranged from a low of 0.19 to a high of 0.99. The Biotechnology industry median Equity-to-Asset is 0.68. Viking Therapeutics' value of 0.78 is 14.7% above this industry median. Based on the distribution chart, Viking Therapeutics ranks #534 out of 1416 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Viking Therapeutics has a GF Score™ of 38/100, reflecting its overall financial health beyond just this single metric.
How does Viking Therapeutics' Equity-to-Asset compare to DYN and CELC?
According to the Biotechnology industry distribution chart, Viking Therapeutics ranks #534 out of 1416 companies for Equity-to-Asset. This puts Viking Therapeutics in the upper half of its industry. The industry median Equity-to-Asset is 0.68. Viking Therapeutics' value of 0.78 is 14.7% above this benchmark. Historically, Viking Therapeutics' own Equity-to-Asset has ranged from 0.19 to 0.99 over the past decade. While the company's 10-year median is 0.96 vs. the industry median of 0.68, Viking Therapeutics has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Equity-to-Asset for a Biotechnology company?
The median Equity-to-Asset among Biotechnology companies is 0.68, based on 1,416 companies in the industry. Companies in the top quartile (top 25%) have a Equity-to-Asset significantly above this median, while those in the bottom quartile fall well below. However, Equity-to-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Viking Therapeutics's current Equity-to-Asset of 0.78 is 14.7% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Equity-to-Asset mean?
A high Equity-to-Asset can signal that a stock is expensive relative to its fundamentals. Equity-to-asset ratio equals total company equity divided by total assets. It measures financial leverage. View historical data on Viking Therapeutics and its competitors. For the Biotechnology industry, the median Equity-to-Asset is 0.68 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Viking Therapeutics's current Equity-to-Asset is 0.78, which is 19% below median its own 10-year median of 0.96. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Viking Therapeutics stock overvalued right now?
Viking Therapeutics (STU:1VT) has a current Equity-to-Asset of 0.78. The current Equity-to-Asset is 0.78, which is 19% below median its 10-year median of 0.96 and 14.7% above the Biotechnology industry median of 0.68. Viking Therapeutics' overall GF Score™ is 38/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Equity-to-Asset calculated?
Equity-to-Asset is calculated from a company's financial statements. For Viking Therapeutics (STU:1VT), the current Equity-to-Asset is 0.78 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Viking Therapeutics Inc is a healthcare service provider. The company specializes in the area of biopharmaceutical development focused on metabolic and endocrine disorders. The company's clinical program pipeline consists of VK2809, VK5211, and VK0214 products. VK2809 and VK0214 are orally available, tissue and receptor-subtype-selective agonists of the thyroid hormone receptor beta. VK5211 is an orally available, non-steroidal selective androgen receptor modulator.
38GF Score
Get the complete analysis for STU:1VT
Equity-to-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
STU:1VT has been successfully added to your 
